ArticleJournal of translational medicine2026
Eugenoplatin (a phyto-chemo drug conjugate) targets cancer stem cells through inhibition of the β-catenin signaling in triple-negative breast cancer cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most prevalent and leading cause of cancer-related mortality among women worldwide. The triple-negative subtype, the most aggressive form of the disease, is associated with the poorest prognosis. In order to improve the treatment of these patients, we have synthesized a phyto-chemo drug conjugate composed of cisplatin and eugenol, two molecules with synergistic anti-cancer effects.
methodsEugenoplatin was synthesized and characterized by HPLC, LC/MS, and 1H-NMR, while its physicochemical properties were predicted by in silico analysis using the Biovia Discovery Studio. The cytotoxic effects of eugenoplatin were first tested in vitro using the WST1 and the flow cytometry techniques. Cell proliferation, migration, and invasion abilities were assessed using the xCELLigence Real-Time Cell Analysis. The changes in gene expression were determined by proteomics analysis (LC/MS), immunoblotting, immunofluorescence, and quantitative RT-PCR. The effect of the drug on breast cancer stem cells was determined by the tumorsphere formation assay, and cell sorting was utilized to isolate a specific breast cancer sub-population of cells. Furthermore, orthotopic tumor xenografts were used to test the potential therapeutic value of eugenoplatin in vivo.
resultsThe novel DNA-damaging molecule (eugenoplatin) has shown higher cytotoxicity through induction of apoptosis, and strong inhibition of cell growth via cell cycle delay at G2/M phase in different cell lines. In addition, eugenoplatin targeted cancer stem cells through inhibition of the β-catenin signaling pathway. These effects were confirmed in humanized orthotopic tumor xenografts, wherein the eugenoplatin-dependent tumor growth inhibition was more than 10-fold stronger than the cisplatin repressive effect, with a potent inhibitory effect on cancer stem cell biomarkers. This was associated with the suppression of various cancer-related signaling pathways, including STAT3/NF-κB, AKT/mTOR, and ERK. Furthermore, eugenoplatin down-regulated the pro-angiogenic factors VEGF-A, IL-6, and IL-8, and repressed angiogenesis both in vitro and in tumor xenografts. In silico analysis has suggested good permeability, good absorption, and higher bioavailability for eugenoplatin, which is also unlikely to be mutagenic, carcinogenic, or hepatotoxic.
conclusionThese results indicate that eugenoplatin, a novel DNA-damaging agent that can also target cancer stem cells, could be of great therapeutic value for TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.